According to a recent LinkedIn post from Cleerly, the company is emphasizing the clinical relevance of differentiating between hard, calcified plaque and soft, non‑calcified plaque in coronary arteries. The post highlights that soft plaque is described as more dangerous, more prone to rupture, and more likely to be missed by traditional diagnostic tests.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post suggests that Cleerly’s technology uses non‑invasive CCTA imaging with advanced plaque analysis to color‑code and quantify all coronary plaque types. This positioning underscores a potential value proposition in improving detection of high‑risk plaque compared with conventional methods.
The post also references the availability of a new Category I CPT code and broader insurance coverage for the technology, indicating that Cleerly’s offering is now reimbursable for a majority of insured lives in the U.S. If adoption follows reimbursement, this could support higher utilization rates, potentially improving revenue visibility and accelerating commercialization.
For investors, the mention of expanded coverage and standardized CPT coding may signal reduced reimbursement friction for providers considering integrating Cleerly’s platform. This development could strengthen Cleerly’s competitive stance in AI‑enabled cardiac imaging and may enhance its attractiveness to strategic partners and payors in the broader cardiovascular diagnostics market.